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Abstract
A new chemical series of antiproliferative compounds was identified via high-
throughput screening on DU-145 human prostate carcinoma cell line (hit compound
potency - 5.7 μM). Exploration of the two peripheral diversity vectors of the hit mole-
cule in a hit-targeted library and testing of the resulting compounds led to SAR gen-
eralizations and identification of the ‘best’ pharmacophoric moieties. The latter were
merged in a single compound that exhibited a 200-fold better potency than the ori-
ginal hit compound. Specific cancer cell cytotoxicity was confirmed for the most
potent compounds.
Background
Prostate cancer is the number one cancer diagnosed in men today. While it occurs
to certain extent throughout the world (least commonly in Eastern/Southern Asia), it
is viewed as the major public health threat in Western Europe and, especially, the
United States [1]. In the US alone, it has been estimated [2] that 186,295 new cases
of prostate cancer (mostly - among men over fifty) were diagnosed in 2008, account-
ing for 25% of all cancers diagnosed in men that year and 10% of the total cancer-
related mortality. Appropriate diet (including dietary supplements) and exercise are
currently the common themes for prostate cancer prevention while classical treat-
ments are limited to surgery, radiation therapy, and hormone therapy. Chemotherapy
of late-stage prostate cancer is still largely experimental; however, it may lead to
increased survival in the future [3]. Specifically, small molecules as well as antibodies
targeted at disrupting vital signaling pathways in cancerous cells have a potential to
provide new basis for innovative treatment of proliferative disorders as prostate can-
cer in the years to come [4].
Results and discussion
The present study was a part of an ongoing effort [5] in our laboratories to find
novel antiproliferative agents as potential treatments for prostate cancer. It was
aimed at identifying new small heterocyclic molecules in Chemical Diversity Research
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would be specifically inhibitory to DU-145 human prostate carcinoma cell line (a
‘classical’ cell line of androgen-independent prostate cancer [6]) while exhibiting no
non-specific (general) cytotoxicity. High-throughput screening of a highly diverse set
of over 5,000 compounds comprising over 200 chemical classes led to several con-
firmed hit classes.
Among these, one hit compound, 1 (Figure 1), that exhibited inhibition of DU-145
cell proliferation in dose-response manner, attracted our attention due to its drug-like-
ness [7], structural simplicity and the presence in its structure of two distinct types of
peripheral appendages (thus allowing for informative SAR exploration).
Herein we report on the synthesis and potency characterization of twenty analogs of
the hit compound 1 leading to the initial SAR generalizations in this chemical class
and to significant improvement of the inhibitory potency as well as to confirmation
that the most potent compounds synthesized in this work inhibit DU-145 proliferation
in a cell-specific manner rather than via general cytotoxicity.
To confirm that the observed activity of 1 w a si n d e e da s s o c i a t e dw i t ht h eN-aryl-N-
(3-aryl-1,2,4-oxadiazol-5-yl)amines chemotype and to obtain initial SAR clues for
further potency optimization, we synthesized a library of 176 analogs 2 of the hit com-
pound. According to the literature [8], N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines 2
can be prepared in moderate yields by reaction of 2 eq. of carbodiimides with amidox-
imes (3). The target products 2 were isolated and purified chromatography on silica
gel using 5-25% EtOAc in hexanes as a mobile phase. The amidoximes 3 were conve-
niently synthesized in nearly quantitative yields from corresponding benzonitriles
(R1CN) (Scheme 1).Scheme 1
Preparation of N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines 2 [8]. Reagents and condi-
tions: (a) hydroxylamine hydrochloride (1 eq.), EtOH, reflux, 5-10 h; (b) aq. Na2CO3,
extraction with EtOAc; (c) 0.2 M solution of 3 in dry DMF, 2.1 eq. of R2-N = C = N-
R2 carbodiimides, 120°C, 18-36 h.
Compounds 2 were tested at 10 μM concentration for inhibition of DU-145 cell prolif-
eration. 19 compounds with inhibition >50% were selected for dose-response experi-
ments to determine IC50 values. The results are presented in Table 1.
There was a clear preference of electron-rich or unsubstituted phenyls in the ‘western’
aryl portion of the molecule with notorious presence of meta-methoxy substituent in 14
active compounds out of 19 compounds for which dose-response curves were obtained. As
N
N
O
NH O
F
1, IC50 = 5.7 ± 0.32 µM
Figure 1 Structure of the hit compound identified in DU-145 cell proliferation HTS.
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Page 2 of 7Table 1 Structures, preparative yields (from 3), and DU-145 proliferation inhibition data
of compounds 2a-s.
Compound R1 R2 Yield, % IC50, μM
a
2a
b 62 2.2 ± 0.30
2b 68 0.86 ± 0.10
2c 70 1.6 ± 0.25
2d 29 2.6 ± 0.35
2e 43 1.0 ± 0.01
2f 43 1.0 ± 0.12
2g 73 2.7 ± 0.22
2h 37 1.6 ± 0.14
2i 77 0.64 ± 0.025
2j 56 0.55 ± 0.010
2k 81 0.084 ± 0.005
2l 54 2.7 ± 0.50
2m 46 0.96 ± 0.08
2n 72 0.93 ± 0.009
2o 75 1.8 ± 0.30
2p 82 2.1 ± 0.17
2q 65 0.91 ± 0.07
2r 66 1.5 ± 0.09
2s 55 0.38 ± 0.024
aIC50 values have been evaluated for standard error. The values reported are the mean of 2 determinations, standard
error provided.
b Compound 2a reffered in this table is indetical with the hit compound 1 in the text and figure 1.
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Page 3 of 7to the ‘eastern’ arylamino portion, the best activity was observed for para-methoxyanilino
substituent (2k and 2s). Notably, presence of electron-withdrawing or ortho-substituents
in the arylamino portion of 2 rendered such compounds less active or completely devoid
of inhibitory potency. This observation is illustrated by several examples provided in
Figure 2.
These SAR observations are useful in determining the ‘activity’ chemistry space for
future optimization of the series. To test our generalizations, we decided to com-
bined the para-methoxy substituent in the ‘eastern’ arylamino portion of the mole-
cule with another beneficial feature - namely, meta-methoxy substituent in the
‘western’ aryl portion (vide supra). Indeed, the activity of the synthesized SAR-guided
compound 2t (Figure 3) improved nearly three-fold compared to 2k, thus demon-
strating the synergy of effects of these two substituents on the inhibitory potency of
the series.
Having improved the antiproliferative potency of the series by two orders of magni-
tude, we then investigated the specificity of the cytotoxicity of the most potent com-
pounds. The general, non-specific cytotoxicity of the most potent three representative
compounds (2j, 2s and 2t with IC50 values of 0.55, 0.38 and 0.029 μM, respectively)
was measured on HepG2 and DU-145 cell lines using a known cytotoxic compound,
digitonin, as a positive control (Figure 4). None of these compounds exhibited cyto-
toxicity in excess of 20% at concentrations as high as 50 μM, while digitonin itself
caused 100% cell death in nanomolar concentration range. Thus, the observed antipro-
liferative activity of the most potent compounds in the series is not due to non-specific
cytotoxicity but must be attributed to a specific cellular target and is selective towards
human prostate carcinoma cells.
N
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O
2t, IC50 = 0.029 ± 0.003 µM
Figure 3 The ‘best’ SAR-merging compound 2t.
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Figure 2 Examples of inactive or poorly active (% inhibition < 20% at 10 μM) compounds 2.
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Cell sources: the prostate cancer Du-145 cell line was purchased from the American
Type Cell Collection (HTB-81). Du-145 was cultured in RPMI-1640 complemented
with 10% fetal bovine serum and 2 mM L-glutamine. To our delight, 80% of the
library screened exhibited >20% inhibition of DU-145 proliferation. The hepatocellu-
lar carcinoma HepG2 cell line was purchased from the American Type Cell Collec-
tion (HB-8065) and was cultured in DMEM complemented with 10% fetal bovine
serum and 2 mM L-glutamine.
Assays description
1. Biological assay to determine inhibition of proliferation of the DU-145 cells
Du-145 cells were plated in 384-well plate at the density of 4000 cells per well. 4 mM
solutions of compounds in DMSO were diluted 100 times with medium and added to
cells to a final concentration of 20 μM( 4 0μLo fc e l lc u l t u r ep l u s4 0μL of compound
solution, final concentration of DMSO - 0.5%). Taxol at the final concentration of 1
μM was used as a positive control. The cells were incubated with compounds for 3
days. Alamar Blue was then added to the cells to a final concentration of 50 μM. After
incubation for 4-6 hours at 37°C, plate fluorescence was read using fluorescence plate
reader Wallac 1420 (530 nm excitation filter, 590 nm emission filter). Proliferation
inhibition was calculated using formula:
%INH F F F negative negative positive   100*(( ) /( ) readout signal ) ),
where
Fnegative: DMSO added to the cells (viable cells) and
Fpositive: taxol (1 uM) added to cells (cell count on 1
st day of incubation)
2. Cytotoxicity assay
For cytotoxicity experiments, higher seeding densities (10,000 or 20,000 cells per well)
were used to more accurately observe potentially diminishing number of cells. This is
in contrast with the measurement of antiproliferative activity where initial seeding den-
sity (4,000 cells per well) was chosen to allow more room for cell proliferation. Thus,
Du-145 or HepG2 cells were plated in 384-well plate at the density of 10,000 or 20,000
cells per well, respectively. Serial dilutions (200×) of the tested compounds in DMSO
were prepared. After that compounds were diluted 100 times in medium and added to
the cells (40 μL of cell culture plus 40 μL of compound solution, final concentration of
DMSO - 0.5%). The cells were incubated with compounds overnight. Known toxic
Figure 4 Cytotoxicity of the most active compounds prepared in this work and digitonin measured
on HepG2 (A) and DU-145 (B) cells.
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Page 5 of 7compound digitonin was used as control. The next day Alamar Blue was added to the
cells to final concentration of 50 μM. After incubation for 4-6 hours at 37°C, plate
fluorescence was read using fluorescence plate reader Wallac 1420 (PerkinElmer) (530
nm excitation filter, 590 nm emission filter). Compound cytotoxity was calculated
using formula:
%TOX F F F negative negative positive   100*(( ) /( compound signal ) )),
where
Fnegative - DMSO was added to cells (viable cells)
Fpositive - digitonin was added to cells (dead cells)
Conclusions
In conclusion, we have undertaken hit expansion and SAR exploration of a new anti-
proliferative chemical series, N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines. This study
led to identification of the new ‘best’ peripheral moieties which, when combined in the
same compound (2t) led to significant improvement of the DU-145 proliferation inhi-
bitory potency (>200-fold compared to the initial hit compound 1). We also demon-
strated that the observed antiproliferative activity of the compounds belonging to the
studied chemotype was not due to non-specific cytotoxicity. The compound 2t repre-
sents a promising new lead for development of novel therapeutic agents for treatment
of androgen-independent prostate cancer. The specific cellular mechanism of action of
this compound remains to be investigateda n dw i l lb ep r e s e n t e di ns u b s e q u e n t
communication.
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